Recent analysis reveals limited evidence on liver support systems’ efficacy for acute liver failure, with unclear benefits and risks for patients awaiting transplants or recovery.
Acute liver failure (ALF) affects approximately thousands of adults annually in the U.S., with a high 30-day mortality rate without intervention. Liver support systems (LSS), designed to temporarily detoxify blood, remain controversial due to inconsistent clinical trial data. A review of 11 studies—published between 1973-2019—found no definitive evidence that LSS improves survival, reduces transplant needs, or mitigates complications like hepatic encephalopathy. The research, conducted across various countries, included 681 participants with ALF caused by drug overdoses, viral hepatitis, or alcohol toxicity.
How Liver Support Systems Work
LSS devices function through two mechanisms: artificial systems (e.g., adsorption columns, hemodialysis) remove toxins via physical filtration, while bioartificial systems (e.g., hepatocyte-based devices) attempt to mimic liver metabolism. The latter are not commercially available, per the review. Both types require venous access and continuous monitoring, with risks including bleeding, infection, and clotting disorders.
In Plain English: The Clinical Takeaway
- There is no strong evidence that liver support systems improve survival or reduce complications in acute liver failure.
- Results vary widely between studies, with most trials being small and poorly designed.
- Patients with acute liver failure should focus on managing underlying causes and preparing for potential liver transplantation.
Deep Dive: Study Limitations and Regional Implications
The review highlighted significant gaps in research quality. Of the 11 studies, nine were single-center trials with fewer than 100 participants, and only two were randomized controlled trials (RCTs). Funding sources were disclosed in seven studies, with four receiving industry support.
Regulatory agencies like the FDA and EMA have not approved LSS as a standalone treatment. In the U.S., the FDA classifies artificial LSS as a Class III medical device, requiring premarket approval. However, many devices remain in clinical use under “compassionate use” protocols. The NHS in the UK includes LSS in its guidelines for ALF management but emphasizes that “evidence of clinical benefit remains inconclusive.”
| Study Characteristics | Key Findings |
|---|---|
| Sample Size | 539
Dr. Priya Deshmukh - Senior Editor, Health OpenAI Adds Scheduled Tasks Feature to ChatGPTSamsung Galaxy M47 Price in India Revealed: Variant-Wise Prices, Launch Offers, and Amazon Prime Day Discount Details |